Health Trials

SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution in Acute HF

ConditionsHeart Failure AcuteDiabetes Type 2Heart Failure With Reduced Ejection FractionHeart Failure With Preserved Ejection Fraction
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age40-89
SponsorUniversity of Palermo

About this trial

The purpose of the current investigation is to demonstrate the efficacy of high-dose furosemide plus small-volume hypertonic saline solution and a Sodium-Glucose cotransporter-2 (SGLT-2) inhibitor among patients admitted for acute exacerbation of heart failure, in determining a significant increase in diuresis and natriuresis. It is also accompanied by a rapid reduction in body weight and a substantial decrease in hospitalization length without compromising renal function.

Eligibility criteria

Qualifiers

acute heart failure;

diabetes type 2.

Disqualifiers

low estimated glomerular filtration rate;

hypernatremia;

diabetes type 1;

non-cardiac causes of dyspnea;

Trial design

Treatments tested in this trial

  • Dapagliflozin tablet
  • Hypertonic Saline Solution, 1 Ml
  • Furosemide Injection

Treatment groups

544 Participants
are divided into 4 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

University of Palermo

Lead sponsor

Source ClinicalTrials.gov